Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9994805 | 0.83 | TSHR (0.48) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL5052638 | 0.81 | TSHR (0.48) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL11058201 | 0.81 | TSHR (0.47) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL11702931 | 0.80 | TSHR (0.46) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL10702026 | 0.80 | TSHR (0.47) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL905094 | 0.79 | TSHR (0.44) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL8861439 | 0.78 | TSHR (0.53) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL5052502 | 0.78 | TSHR (0.51) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL4776174 | 0.76 | TSHR (0.50) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL6368712 | 0.75 | TSHR (0.58) | TSHRALDH1A1TP53HIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517870-A2 | METHOD FOR ACCELERATING SETTING OF A HYDRAULIC MINERAL BINDER COMPOSITION WITH ADDED ADJUVANT INCLUDING HYDROPHILIC FUNCTIONS, AND COMPOSITION OBTAINABLE BY SAID METHOD AND USE THEREOF | RHODIA CHIMIE (FR) | 2005-03-30 | — | — | EP | disclosed |
| US-20040170657-A1 | Dispersion comprising an emulsion having an aqueous phase with high ionic strength | RHODIA CHIMIE (FR) | 2004-09-02 | — | — | US | disclosed |
| WO-2004002915-A2 | METHOD FOR ACCELERATING SETTING OF A HYDRAULIC MINERAL BINDER COMPOSITION WITH ADDED ADJUVANT INCLUDING HYDROPHILIC FUNCTIONS, AND COMPOSITION OBTAINABLE BY SAID METHOD AND USE THEREOF | RHODIA CHIMIE (FR) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040170657-A1 | Dispersion comprising an emulsion having an aqueous phase with high ionic strength | SAMM50, IPO5, IPO7 | TSHR 4792/4885ALDH1A1 4658/4885TP53 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.